Foundation Medicine, Inc. (FMI) Release: FoundationOne™ Heme Enables Identification Of Genomic Alterations Not Identified By Conventional Methods Across Hematologic Malignancies
12/9/2013 10:13:21 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine today announced new data demonstrating that its fully informative genomic profile for hematologic cancers, FoundationOne™ Heme, can be performed in routine clinical cancer specimens to identify all classes of genomic alterations, including gene fusions, across hundreds of genes related to oncogenesis in patients with hematologic malignancies. These data were presented today in an oral presentation titled Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay (abstract number 230) by Ross L. Levine, M.D., hematologist/oncologist and associate member, Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center, at the American Society of Hematology Annual Meeting in New Orleans.
Help employers find you! Check out all the jobs and post your resume.
comments powered by